The second method involves establishing each patient’s lowest PSA level (nadir) over the course of 6 months of treatment with 5ARIs, then monitoring for any confirmed increase from that baseline as a potential indicator of prostate cancer [3, 23]. This evidence concerns the gene KLK3 and prostate carcinoma.